Renalytix plc (RENXF) Financial Statements (2026 and earlier)
Company Profile
| Business Address |
FINSGATE LONDON, EC1V 9EE |
| State of Incorp. | DE |
| Fiscal Year End | June 30 |
| Industry (SIC) | 8071 - Medical Laboratories (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)Annual | Quarterly
| 9/30/2024 Q1 | 6/30/2024 Q4 | 3/31/2024 Q3 | 12/31/2023 Q2 | 9/30/2023 Q1 | 6/30/2023 Q4 | |||
|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||
| Current Assets | ||||||||
| Cash, cash equivalents, and short-term investments | 4,680 | 4,704 | 5,619 | 13,891 | ||||
| Cash and cash equivalent | 4,680 | 4,704 | 5,619 | 13,891 | ||||
| Receivables | 722 | 554 | 1,370 | 1,014 | ||||
| Other undisclosed current assets | 716 | 1,082 | 1,261 | 1,566 | ||||
| Total current assets: | 6,118 | 6,340 | 8,250 | 16,471 | ||||
| Noncurrent Assets | ||||||||
| Operating lease, right-of-use asset | 102 | 131 | ||||||
| Property, plant, and equipment, after accumulated depreciation, depletion, and amortization | 216 | 230 | 576 | 944 | ||||
| Intangible asset, including goodwill, after accumulated amortization | 869 | 913 | 965 | 974 | ||||
| Intangible asset, excluding goodwill, after accumulated amortization | 869 | 913 | 965 | 974 | ||||
| Other undisclosed noncurrent assets | 769 | 1,286 | 1,383 | 1,020 | ||||
| Total noncurrent assets: | 1,854 | 2,429 | 3,026 | 3,069 | ||||
| TOTAL ASSETS: | 7,972 | 8,769 | 11,276 | 19,540 | ||||
| LIABILITIES AND EQUITY | ||||||||
| Liabilities | ||||||||
| Current Liabilities | ||||||||
| Accounts payable and accrued liabilities | 3,354 | 4,273 | 4,259 | 4,566 | ||||
| Accrued liabilities | 3,354 | 4,273 | 4,259 | 4,566 | ||||
| Debt | 4,159 | 4,449 | 3,063 | 4,569 | ||||
| Other undisclosed current liabilities | 3,982 | 6,266 | 6,600 | 6,038 | ||||
| Total current liabilities: | 11,495 | 14,988 | 13,922 | 15,173 | ||||
| Noncurrent Liabilities | ||||||||
| Long-term debt and lease obligation | 4,331 | 4,892 | 5,310 | 5,848 | ||||
| Long-term debt, excluding current maturities | 4,331 | 4,892 | 5,310 | 5,848 | ||||
| Liabilities, other than long-term debt | 10 | |||||||
| Operating lease, liability | 10 | |||||||
| Total noncurrent liabilities: | 4,331 | 4,892 | 5,310 | 5,858 | ||||
| Total liabilities: | 15,826 | 19,880 | 19,232 | 21,031 | ||||
| Equity | ||||||||
| Equity, attributable to parent | (7,854) | (11,111) | (7,956) | (1,491) | ||||
| Common stock | 478 | 368 | 305 | 290 | ||||
| Additional paid in capital | 204,893 | 194,786 | 190,437 | 188,031 | ||||
| Accumulated other comprehensive loss | (1,443) | (1,558) | (1,734) | (1,333) | ||||
| Accumulated deficit | (211,782) | (204,707) | (196,964) | (188,479) | ||||
| Total equity: | (7,854) | (11,111) | (7,956) | (1,491) | ||||
| TOTAL LIABILITIES AND EQUITY: | 7,972 | 8,769 | 11,276 | 19,540 | ||||
Income Statement (P&L) ($ in thousands)Annual | Quarterly
| 9/30/2024 Q1 | 6/30/2024 Q4 | 3/31/2024 Q3 | 12/31/2023 Q2 | 9/30/2023 Q1 | 6/30/2023 Q4 | ||
|---|---|---|---|---|---|---|---|
| Revenues | 586 | 535 | 709 | 459 | |||
| Cost of revenue | (550) | (601) | (480) | (502) | |||
| Gross profit: | 36 | (66) | 229 | (43) | |||
| Operating expenses | (5,561) | (6,487) | (8,870) | (8,846) | |||
| Other undisclosed operating loss | |||||||
| Operating loss: | (5,525) | (6,553) | (8,641) | (8,889) | |||
| Nonoperating income (expense) | (15) | (34) | 72 | 389 | |||
| Gain (loss), foreign currency transaction, before tax | (52) | 15 | (89) | 289 | |||
| Other nonoperating income (expense) | 37 | (49) | 161 | 100 | |||
| Other undisclosed loss from continuing operations before equity method investments, income taxes | (4,256) | ||||||
| Loss from continuing operations before equity method investments, income taxes: | (9,796) | (6,587) | (8,569) | (8,500) | |||
| Other undisclosed income (loss) from continuing operations before income taxes | 2,722 | (1,156) | 88 | (1,654) | |||
| Loss from continuing operations before income taxes: | (7,074) | (7,743) | (8,481) | (10,154) | |||
| Income tax expense | (4) | ||||||
| Net loss available to common stockholders, diluted: | (7,074) | (7,743) | (8,485) | (10,154) | |||
Comprehensive Income ($ in thousands)Annual | Quarterly
| 9/30/2024 Q1 | 6/30/2024 Q4 | 3/31/2024 Q3 | 12/31/2023 Q2 | 9/30/2023 Q1 | 6/30/2023 Q4 | ||
|---|---|---|---|---|---|---|---|
| Net loss: | (7,074) | (7,743) | (8,485) | (10,154) | |||
| Comprehensive loss: | (7,074) | (7,743) | (8,485) | (10,154) | |||
| Comprehensive loss, net of tax, attributable to noncontrolling interest | (6,959) | (7,567) | (8,886) | (10,037) | |||
| Comprehensive loss, net of tax, attributable to parent: | (14,033) | (15,310) | (17,371) | (20,191) | |||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.